The modified COVID-19 Yorkshire Rehabilitation Scale (C19-YRSm) patient-reported outcome measure for Long Covid or Post-COVID-19 syndrome.
COVID-19
PACS
PROM
SARS-CoV2
instrument
phenotypes
scale
traits
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
17
05
2022
received:
09
04
2022
accepted:
18
05
2022
pubmed:
24
5
2022
medline:
16
7
2022
entrez:
23
5
2022
Statut:
ppublish
Résumé
The C19-YRS is the literature's first condition-specific, validated scale for patient assessment and monitoring in Post-COVID-19 syndrome (PCS). The 22-item scale's subscales (scores) are symptom severity (0-100), functional disability (0-50), additional symptoms (0-60), and overall health (0-10). This study aimed to test the scale's psychometric properties using Rasch analysis and modify the scale based on analysis findings, emerging information on essential PCS symptoms, and feedback from a working group of patients and professionals. Data from 370 PCS patients were assessed using a Rasch Measurement Theory framework to test model fit, local dependency, response category functioning, differential item functioning, targeting, reliability, and unidimensionality. The working group undertook iterative changes to the scale based on the psychometric results and including essential symptoms. Symptom severity and functional disability subscales showed good targeting and reliability. Post hoc rescoring suggested that a 4-point response category structure would be more appropriate than an 11-point response for both subscales. Symptoms with binary responses were placed in the other symptoms subscale. The overall health single-item subscale remained unchanged. A 17-item C19-YRSm was developed with subscales (scores): symptom severity (0-30), functional disability (0-15), other symptoms (0-25), and overall health (0-10).
Sections du résumé
BACKGROUND
The C19-YRS is the literature's first condition-specific, validated scale for patient assessment and monitoring in Post-COVID-19 syndrome (PCS). The 22-item scale's subscales (scores) are symptom severity (0-100), functional disability (0-50), additional symptoms (0-60), and overall health (0-10).
OBJECTIVES
This study aimed to test the scale's psychometric properties using Rasch analysis and modify the scale based on analysis findings, emerging information on essential PCS symptoms, and feedback from a working group of patients and professionals.
METHODS
Data from 370 PCS patients were assessed using a Rasch Measurement Theory framework to test model fit, local dependency, response category functioning, differential item functioning, targeting, reliability, and unidimensionality. The working group undertook iterative changes to the scale based on the psychometric results and including essential symptoms.
RESULTS
Symptom severity and functional disability subscales showed good targeting and reliability. Post hoc rescoring suggested that a 4-point response category structure would be more appropriate than an 11-point response for both subscales. Symptoms with binary responses were placed in the other symptoms subscale. The overall health single-item subscale remained unchanged.
CONCLUSION
A 17-item C19-YRSm was developed with subscales (scores): symptom severity (0-30), functional disability (0-15), other symptoms (0-25), and overall health (0-10).
Identifiants
pubmed: 35603810
doi: 10.1002/jmv.27878
pmc: PMC9348420
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4253-4264Informations de copyright
© 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.
Références
EClinicalMedicine. 2021 Aug;38:101019
pubmed: 34308300
BMJ Open. 2022 May 17;12(5):e063505
pubmed: 35580970
Arthritis Rheum. 2007 Dec 15;57(8):1358-62
pubmed: 18050173
Nat Commun. 2022 Apr 12;13(1):1957
pubmed: 35413949
J Med Virol. 2022 Mar;94(3):1027-1034
pubmed: 34676578
Expert Rev Pharmacoecon Outcomes Res. 2011 Oct;11(5):571-85
pubmed: 21958102
Appl Psychol Meas. 2017 May;41(3):178-194
pubmed: 29881087
J Appl Meas. 2009;10(4):348-54
pubmed: 19934524
J Med Virol. 2022 Apr;94(4):1419-1427
pubmed: 34783052
BMJ Open Respir Res. 2021 Nov;8(1):
pubmed: 34764200
BMJ. 2022 Jan 28;376:o257
pubmed: 35091425
J Med Virol. 2022 Sep;94(9):4253-4264
pubmed: 35603810
BMJ Glob Health. 2021 Sep;6(9):
pubmed: 34551971
J Med Virol. 2021 Feb;93(2):1013-1022
pubmed: 32729939
Soc Sci Med. 2021 Jan;268:113426
pubmed: 33199035
J Rehabil Med. 2020 May 25;52(5):jrm00063
pubmed: 32449782
J Appl Meas. 2002;3(2):205-31
pubmed: 12011501
Int J Nurs Stud. 2009 Mar;46(3):380-93
pubmed: 19059593
Int J Environ Res Public Health. 2020 Sep 05;17(18):
pubmed: 32899534
J Rehabil Med. 2020 Aug 24;52(8):jrm00089
pubmed: 32830284
Lancet Respir Med. 2021 Nov;9(11):1275-1287
pubmed: 34627560